Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Tuesday's Featured News 3 Undervalued Names Too Cheap to IgnoreAuthored by Nathan Reiff. Article Posted: 3/7/2026. 
Key Points - Several established companies present potential value plays in early 2026 thanks to comparably low P/E ratios and strong fundamentals, despite broader market challenges.
- Merck's recent rally has not compromised its P/E ratio, which remains below the industry average, as the company navigates new ways to grow revenue amid its flagship Keytruda nearing patent expiration.
- Campbell's and US Foods offer contrasting cases: the former experiencing a sharp pullback and a high dividend yield, while the latter rallying amid adjusted EBITDA gains and the potential for further improvement.
- Special Report: The Biggest IPO Ever: Claim Your Stake Today
Highly publicized growth trajectories of some of the biggest companies out there may make it seem like 2026 is not a prime time for a value strategy. Still, a number of sizable firms are trading at attractive valuations and offer potential for share-price appreciation alongside fundamental growth. The companies below represent potential value plays, with valuation metrics that are either historically low or competitive relative to peers or the broader market. They also offer additional benefits, such as compelling dividends or promising new product developments. While value opportunities may be harder to find when many promising companies have regained investor attention — and some apparent value names have deteriorating operations or other red flags — well-established and stable names can still be attractive prospects. Even After Rally, Merck May Be Undervalued, With Careful Planning for Keytruda in the Works Med-X is gearing up for a possible Nasdaq listing (ticker: MXRX). But the real opportunity is now – before they hit the big stage.
Their all-natural pesticides have outperformed chemical brands in independent lab tests, providing safer solutions without sacrificing results.
With $6.4M in sales in just four years, they're getting ready for the next step. Become a Med-X Shareholder Before Their Nasdaq Plans Unfold Although shares have climbed by more than 28% over the past year — bringing its market capitalization to nearly $300 billion — biopharma giant Merck & Co. Inc. (NYSE: MRK) still sports a price-to-earnings (P/E) ratio of 16.45, well below the medical industry average of close to 27. Analysts expect continued growth: the company is projected to see earnings rise by nearly 10% in the coming year and has a about 5% upside in the near term. Driving Merck's momentum is its pembrolizumab cancer drug, Keytruda, which received approval for subcutaneous injection from the European Commission in late 2025 and generated roughly $8.4 billion in sales in Q4 2025 — an increase of almost 7% year-over-year (YOY). Keytruda also shows potential in ovarian cancer treatments, which could attract a new group of patients. These factors should help Merck grow revenue as it prepares for Keytruda's expected patent expiration in 2028. Merck's portfolio is broadening: the company recently announced phase 3 trial results for clesrovimab-cfor (Enflonsia), a treatment for RSV in young children. At the same time, Merck is taking strategic steps to prepare for Keytruda's patent loss by splitting its human health branch into two units, which should make it easier to expand non-cancer drug sales. A Difficult External Situation Pressures Campbell's, But Strong Dividend and Value Remain Factors Campbell's (NASDAQ: CPB) shares have fallen about 37% over the last year as the food-and-beverage staple faced pressure from tariffs and inflation. In Q1 fiscal 2026, which ended Nov. 2, 2025, the company posted modest year-over-year declines in organic net sales and consumption, with adjusted earnings per share (EPS) down about 13%. The company has not yet seen notable margin improvement after initiating cost-saving measures. The near term is likely to remain challenging for the iconic food brand, as fiscal-year guidance is weak overall. However, an improving supply chain and strong brand loyalty — especially for its premium offerings — should help protect the business. Shifts in tariff policy could also ease some of the pressure the company faces. On top of that, Campbell's remains a compelling dividend play, offering a yield of 5.9%, though its payout ratio is fairly high at more than 80%. Additionally, Campbell's P/E ratio of 13.5 is the lowest it has been in about four years. Those factors may convince some investors that the stock is worth the risk, despite caution among Wall Street analysts. A Recent US Foods Rally May Continue; Bottom-Line Growth Remains in Place Foodservice distribution leader US Foods (NYSE: USFD) has followed a nearly opposite path to Campbell's — shares have climbed about 33% over the last year. Still, its P/E ratio remains relatively low compared with the broader market at 31.6. On the fundamentals, US Foods is making important strides: the company reported improving profitability in the latest quarter and full-year adjusted EBITDA gains of 11% YOY. Better inventory management and cost-of-goods savings are helping the firm gain traction. With a robust $4 billion capital deployment plan, US Foods is well-positioned to maintain revenue growth momentum and continue its upward trend in adjusted EBITDA. Analysts rate USFD as a Moderate Buy based on 11 Buys and 2 Holds, with roughly 15% upside potential.
| 
